Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Rallybio Corp entered into Collaboration Agreement with Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. valued at $0.5 million (effective 2024-04-09).
- Action
- entry
- Agreement
- collaboration
- Counterparty
- Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc.
- Value
- $0.5 million
- Effective
- 2024-04-09
Exact text from the filing
On April 9, 2024, Rallybio Corporation (the “Company”), through its subsidiary Rallybio IPA, LLC, entered into a collaboration agreement (the “Collaboration Agreement”) with Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. (“J&J”),
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Rallybio Corp entered into Securities Purchase Agreement with Johnson & Johnson Innovation – JJDC, Inc. valued at approximately $6.6 million (effective 2024-04-10).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Johnson & Johnson Innovation – JJDC, Inc.
- Value
- approximately $6.6 million
- Effective
- 2024-04-10
Exact text from the filing
On April 10, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Johnson & Johnson Innovation – JJDC, Inc., a Delaware corporation (the “Purchaser”), pursuant to which the Company sold to the Purchaser, in an unregistered offering (the “Offering”), shares of common stock
View on SEC.gov